D-1332-2020 Class II Terminated
FDA drug recall D-1332-2020 was initiated by Teva Pharmaceuticals USA on Jun 2, 2020 and is designated Class II. Reason for recall: CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level The recall status is terminated (terminated Apr 12, 2024). Affected quantity: a) 15,329 bottles and b) 137 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Jul 1, 2020
- Initiation Date
- Jun 2, 2020
- Termination Date
- Apr 12, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- a) 15,329 bottles and b) 137 bottles
Product description
Metformin Hydrochloride Extended-Release Tablets, USP 750 mg, a) 100 (NDC 62037-577-01) and b) 1000 (NDC 62037-577-10), Rx Only, Manufactured by: Watson Pharma Private Limited, Verna, Salcette Goa, Distributed by: Actavis Pharma, Inc., Parsippany, NJ
Reason for recall
CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level
Distribution pattern
Product was distributed throughout the United States, including Puerto Rico.
Code information
a) 1333338M, exp. date 08/2020, 1333339A, exp. date 08/2020; b) 1354471A, exp. date 02/2021
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1332-2020
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026